Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
Timothy R HodgesJason R AbbottAndrew J LittleDhruba SarkarJames M SalovichJennifer E HowesDenis T AkanJiqing SaiAllison L ArnoldCarrie BrowningMichael C BurnsTammy SobolikQi SunYugandhar BeesettyJesse A CokerDirk ScharnHeinz StadtmuellerOlivia W RossaneseJason PhanAlex G WatersonDarryl B McConnellStephen W FesikPublished in: Journal of medicinal chemistry (2018)
Son of sevenless homologue 1 (SOS1) is a guanine nucleotide exchange factor that catalyzes the exchange of GDP for GTP on RAS. In its active form, GTP-bound RAS is responsible for numerous critical cellular processes. Aberrant RAS activity is involved in ∼30% of all human cancers; hence, SOS1 is an attractive therapeutic target for its role in modulating RAS activation. Here, we describe a new series of benzimidazole-derived SOS1 agonists. Using structure-guided design, we discovered small molecules that increase nucleotide exchange on RAS in vitro at submicromolar concentrations, bind to SOS1 with low double-digit nanomolar affinity, rapidly enhance cellular RAS-GTP levels, and invoke biphasic signaling changes in phosphorylation of ERK 1/2. These compounds represent the most potent series of SOS1 agonists reported to date.